Integra LifeSciences (NASDAQ:IART – Get Free Report) updated its third quarter 2024 earnings guidance on Monday. The company provided EPS guidance of 0.360-0.440 for the period, compared to the consensus EPS estimate of 0.850. The company issued revenue guidance of $372.0 million-$382.0 million, compared to the consensus revenue estimate of $432.1 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.570 EPS.
Integra LifeSciences Stock Performance
NASDAQ IART opened at $24.81 on Thursday. The business’s 50 day moving average price is $29.61 and its 200-day moving average price is $33.46. Integra LifeSciences has a fifty-two week low of $22.36 and a fifty-two week high of $46.09. The company has a market cap of $1.92 billion, a P/E ratio of 49.62, a P/E/G ratio of 1.10 and a beta of 1.11. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 3.39.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last posted its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. The business had revenue of $418.20 million for the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.71 earnings per share. Sell-side analysts predict that Integra LifeSciences will post 2.49 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on IART
Insider Transactions at Integra LifeSciences
In other Integra LifeSciences news, Chairman Stuart Essig purchased 52,641 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The shares were bought at an average price of $28.49 per share, for a total transaction of $1,499,742.09. Following the acquisition, the chairman now owns 487,922 shares in the company, valued at $13,900,897.78. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.10% of the company’s stock.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Recommended Stories
- Five stocks we like better than Integra LifeSciences
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Time To Pick Up the Pieces of Starbucks’ Broken Growth Story
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 AI Stocks That You Can Buy and Hold Forever
- 3 Healthcare Dividend Stocks to Buy
- As The Magnificent 7 Stumble, Pivot to These 3 Growth Stocks
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.